Edgewise Therapeutics

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative small-molecule therapies for severe, rare neuromuscular and cardiac disorders. The company utilizes a proprietary drug discovery platform to target muscle as an organ, aiming to address significant unmet medical needs in conditions like Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and hypertrophic cardiomyopathy (HCM). Headquartered in Boulder, Colorado, Edgewise is committed to advancing its pipeline of novel therapeutics through rigorous clinical development. The company's approach leverages deep expertise in muscle physiology to identify precision medicines that regulate key proteins in muscle tissue, with the goal of improving the lives of patients and families affected by these devastating conditions.